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Relative contributions of preprandial and
postprandial glucose exposures, glycemic
variability, and non-glycemic factors to
HbA1c in individuals with and without
diabetes
Kristine Færch 1, Marjan Alssema2,3, David J. Mela2, Rikke Borg4 and Dorte Vistisen1
Abstract
Background/objective: There is substantial interest in dietary approaches to reducing postprandial glucose (PPG)
responses, but the quantitative contribution of PPG to longer-term glycemic control (reﬂected in glycated
hemoglobin, HbA1c) in the general population is not known. This study quantiﬁed the associations of preprandial
glucose exposure, PPG exposure, and glycemic variability with HbA1c and estimated the explained variance in HbA1c in
individuals with and without type 2 diabetes (T2D).
Subjects/methods: Participants in the A1c-Derived Average Glucose (ADAG) study without T2D (n = 77) or with non-
insulin-treated T2D and HbA1c<6.5% (T2DHbA1c < 6.5%, n = 63) or HbA1c ≥ 6.5% (T2DHbA1c ≥ 6.5%, n = 34) were included
in this analysis. Indices of preprandial glucose, PPG, and glycemic variability were calculated from continuous glucose
monitoring during four periods over 12 weeks prior to HbA1c measurement. In linear regression models, we estimated
the associations of the glycemic exposures with HbA1c and calculated the proportion of variance in HbA1c explained
by glycemic and non-glycemic factors (age, sex, body mass index, and ethnicity).
Results: The factors in the analysis explained 35% of the variance in HbA1c in non-diabetic individuals, 49% in
T2DHbA1c < 6.5%, and 78% in T2DHbA1c ≥ 6.5%. In non-diabetic individuals PPG exposure was associated with HbA1c in
confounder-adjusted analyses (P < 0.05). In the T2DHbA1c < 6.5% group, all glycemic measures were associated with
HbA1c (P < 0.05); preprandial glucose and PPG accounted for 14 and 18%, respectively, of the explained variation. In
T2DHbA1c ≥ 6.5%, these glycemic exposures accounted for more than 50% of the variation in HbA1c and with equal
relative contributions.
Conclusions: Among the glycemic exposures, PPG exposure was most strongly predictive of HbA1c in non-diabetic
individuals, suggesting that interventions targeting lowering of the PPG response may be beneﬁcial for long-term
glycemic maintenance. In T2D, preprandial glucose and PPG exposure contributed equally to HbA1c.
Introduction
Hemoglobin A1c (HbA1c) reﬂects glycemic exposure in
the previous 8–12 weeks1. The level of HbA1c is in
addition to glycemia determined by the lifespan of ery-
throcytes, which is affected by nutritional deﬁciencies, for
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example, iron deﬁciency anemia and vitamin B12 deﬁ-
ciency2. In addition to nutritional deﬁciencies sex, genetic
factors, and hematologic parameters are non-glycemic
factors affecting HbA1c concentrations
1.
High HbA1c concentrations are associated with an
increased risk for cardiovascular disease and mortality in
individuals with and without type 2 diabetes (T2D)3–6.
Individuals without T2D spend a considerable amount of
time during the day at glucose concentrations considered
to be prediabetic (>7.8 mmol/L)7. Accordingly, lifestyle or
pharmaceutical interventions targeting lowering of post-
prandial glucose (PPG) directly or via the underlying
insulin sensitivity are relevant even in the non-diabetic
population8. However, the exact contribution of normally
experienced, daily PPG exposures and daytime glucose
variability to variation in HbA1c in individuals with and
without T2D is currently unknown, because few studies
have captured these ﬂuctuations over sustained periods
under free-living conditions, for example, by use of con-
tinuous glucose monitoring (CGM)8, 9.
In the current analysis, we aimed to compare the
strength of the associations of real-life preprandial and
PPG exposures as well as glycemic variability with HbA1c
concentrations in non-diabetic individuals and in persons
with non-insulin-treated T2D with different levels of
glycemic control. Moreover, we aimed to estimate the
variance in HbA1c concentrations explained by pre-
prandial and PPG exposures, glycemic variability, and
non-glycemic characteristics in these subgroups.
Materials/subjects and methods
Study population
The A1c-Derived Average Glucose (ADAG) study is a
multicenter study including 11 centers in the United
States, Europe, Africa, and Asia. From January 2006 to
March 2008, 268 individuals with T1D, 159 with T2D, and
80 free of diabetes completed a 16-week period of
intensive CGM and self-monitoring of blood glucose
(SMBG). Individuals without diabetes had no family his-
tory of diabetes and a fasting plasma glucose concentra-
tion ≤5.4 mmol/L after an overnight fast. Persons with
diabetes had to have stable glycemic control as evidenced
by two HbA1c values within 1 percentage point (~11
mmol/mol) of each other in the 6 months before
recruitment. Diabetes management was left to the parti-
cipants and their usual health care providers. Individuals
with T1D were not considered in this study because we
did not want to include individuals on insulin treatment.
We further excluded 60 persons with T2D who were
treated with insulin and ﬁve because of missing BMI (two
with diabetes and three without), leaving 77 individuals
without diabetes (non-DM) and 97 participants with T2D
for the present analysis. Participants with T2D were fur-
ther subdivided into those meeting and exceeding the
target HbA1c level for diabetes management of <6.5%/48
mmol/mol (respectively “T2DHbA1c<6.5%,” n= 63; and
“T2DHbA1c≥6.5%,” n= 34).
The ADAG study was approved by the human studies
committees for each of the participating institutions.
Written informed consent was obtained from all partici-
pants before inclusion in the study.
Data collection and study procedures
Characteristics
Clinical data collected at baseline included age, sex,
height, weight, waist circumference, blood pressure, and
treatment with insulin, lipid-lowering, or antihypertensive
medication. Blood samples for HbA1c and plasma lipids
were obtained at baseline and monthly for 3 months (i.e.,
four repeat measurements in total). Information on eth-
nicity was coded as being of white or non-white origin.
Continuous glucose monitoring
Measures of glycemia were performed using the blinded
CGM system (Medtronic Minimed, Northridge, CA,
USA), which measures glucose concentrations every 5
min. The measurements were performed for at least
2 days at baseline and then again for at least 2 days every
4 weeks during the next 12 weeks. At least one successful
24-h proﬁle out of the 2–3 days of monitoring with no
gaps >120 min and a mean absolute difference of <18%
compared with the Hemocue calibration results was
required to be included in the analysis. Measures from the
ﬁrst 2 h of CGM measurement were excluded, since this
period is considered an unstable calibration period. Dur-
ing the CGM measurement periods, the participants
performed daily 8-point SMBG proﬁles with a HemoCue
meter (HemoCue Glucose 201 Plus, Hemocue, Ängel-
holm, Sweden). SMBG was performed right before and 90
min after breakfast, lunch, and dinner as well as at bed-
time and at 3 a.m. The SMBG measurements were used
for calibration purposes, and the time points of SMBG
measurements were used for deﬁnition of preprandial and
postprandial periods.
Laboratory analyses
Blood samples taken at the clinical examinations were
frozen at −80 °C and were sent on dry ice by overnight
shipment to a central laboratory. As the ADAG study was
part of the standardization of HbA1c measurements,
samples for determination of HbA1c were analyzed with
four different DCCT-aligned assays, including a high-
performance liquid chromatography assay (Tosoh G7;
Tosoh Bioscience, Tokyo, Japan), two immunoassays
(Roche A1C and Roche Tina-quant; Roche Diagnostics),
and one afﬁnity assay (Primus Ultra-2; Primus Diag-
nostics, Kansas City, MO, USA). The mean value of the
four HbA1c measurements at the 12-week visit was used
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in the analysis. A detailed description of the study has
been published previously10.
Calculations
HbA1c reﬂects the average glycemia over the preceding
8–12 weeks. Accordingly, the mean values of the different
glycemic measures over the ﬁrst three CGM measure-
ment periods (0, 4, and 8 weeks) were used as explanatory
variables and HbA1c measured at the last visit (12 weeks
of follow-up) was used as outcome (Supplementary Fig-
ure S1). The calculations used to derive these are speciﬁed
below.
Preprandial glycemic measures
A measure of pre-breakfast glycemia was obtained from
the CGM measurements at 0, 4, and 8 weeks as the
average glucose concentration from t=−15min to t= 0
min pre-breakfast. An index of nocturnal glycemia was
calculated as mean glucose concentrations from the CGM
period from 2 a.m. to 4 a.m. from the same visits.
Postprandial glycemic measures
From the CGM data we estimated postprandial periods
as the areas under the glucose curves (AUCs) from time of
intake of breakfast, lunch, and dinner and until 2 h after the
meal intake. These time points were derived from the
SMBG data. The mean AUC of all larger meals (breakfast,
lunch, and dinner) over all measurement days at 0, 4, and
8 weeks was calculated. In addition to the AUCs, we also
calculated mean incremental AUCs as (AUC– (preprandial
glucose concentration × 2 h)) over the same measurement
periods. Additionally, incremental AUCs were averaged for
each meal type (breakfast, lunch, and dinner) over the
three visits and further averaged over meals to provide an
overall mean estimate. Peak glucose was estimated as the
single highest glucose concentration obtained during one
of these CGM measurement periods (0, 4, or 8 weeks).
Glycemic variability
As a measure of glycemic variability the mean ampli-
tude of glycemic excursions (MAGE) was calculated from
CGM data. MAGE is the mean of the differences between
consecutive peaks and nadirs, only including changes >1
SD of glycemic values and thereby only capturing major
ﬂuctuations11, 12. Additionally, the standard deviation
(SD) and coefﬁcient of variation (CV) of the glycemic
values were calculated from the CGM data. CV is the SD
divided by the mean13. Also MAGE, SD, and CV were
averaged over the three ﬁrst visits (0, 4, and 8 weeks).
Statistical analyses
Linear regression analysis was used to estimate the
associations of preprandial glycemia (pre-breakfast glu-
cose and nocturnal glucose), postprandial glycemia (total
AUC, incremental AUC, and peak glucose), as well as
glycemic variability (MAGE, SD, and CV) with HbA1c.
The analyses were stratiﬁed by the three groups (no dia-
betes, T2DHbA1c < 6.5%, and T2DHbA1c ≥ 6.5%). Analyses were
performed without adjustment and with adjustment for
age, sex, BMI, and ethnicity. Prior to analysis, the eight
measures of glycemia were standardized to allow direct
comparisons of the strength of their association with
HbA1c. The corresponding regression coefﬁcients will
thus reﬂect the difference in HbA1c per 1 population SD
difference in the glycemic measures.
In unadjusted linear regression analysis, using the same
three groups, we calculated the proportion of variance in
HbA1c explained by the following categories of glycemic
measures: preprandial glucose (nocturnal and pre-breakfast
glucose), PPG (AUC glucose, incremental AUC glucose
and peak glucose), glycemic variability (MAGE, SD, and
CV), and non-glycemic factors (age, sex, BMI, and ethni-
city). First, we modeled the association between HbA1c and
each of the four categories of glucose measures in order to
estimate their individual contributions to explaining the
variance in HbA1c. Second, the combined contribution of
the four categories of glucose measures was calculated in a
multiple linear regression analysis including all glycemic
measures. Because the four categories of glucose measures
(preprandial glucose, PPG, glycemic variability, and non-
glycemic factors) to some extent are correlated, the sum of
their individual contributions will likely exceed the pro-
portions of variance explained by including all four cate-
gories in the same model. We therefore used the latter
result to scale the individual contributions in order for
them to add up to the total variance explained in HbA1c by
all the measures in combination. We also performed a
sensitivity analysis, including only pre-breakfast glucose,
AUC glucose, and SD as measures of preprandial and
postprandial glycemia and glycemic variability, respectively.
Statistical analyses were performed in R version 3.2.3
(The R Foundation for Statistical Computing) and SAS
version 9.4 (SAS Institute, Cary, NC, USA). A two-sided
P ≤ 0.05 was used as the criterion for statistical sig-
niﬁcance in all analyses.
Results
Clinical characteristics
Table 1 shows the clinical characteristics of the study
participants at baseline stratiﬁed by diabetes status.
Compared to those with T2D, the healthy population
without diabetes was younger and leaner and had a more
favorable cardiometabolic proﬁle as well as a lower use of
lipid-lowering and blood pressure-lowering medications.
Within the T2D population, those with the lower HbA1c
concentration were more likely to be men, and they were
leaner and had lower systolic blood pressure than those
with higher HbA1c concentrations (Table 1).
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Relationships between glycemic measures and HbA1c
concentrations
The median number of days with valid CGM mea-
surements in the study population was 13 with a range
from 3 to 19 days. Pairwise scatter diagrams of the
interrelationships between the eight different glycemic
measures by the three groups (no diabetes, T2DHbA1c <
6.5%, and T2DHbA1c ≥ 6.5%) are shown in Supplementary
Table 1 Characteristics of the study population by glycemic status
No diabetes
(n= 77)
T2DHbA1c < 6.5%
(n= 63)
T2DHbA1c ≥ 6.5%
(n= 34)
Overall
P
Clinical characteristics
Age (years) 41.1 (13.7) 56.0 (10.0)a 53.7 (8.8)a <0.001
Male sex (%) 31.2 (21.1;42.7) 57.1 (44.0;69.5)a 32.4 (17.4;50.5)b 0.004
White ethnicity (%) 68.8 (57.3;78.9) 76.2 (63.8;86.0) 50.0 (32.4;67.6)b 0.034
Weight (kg) 72.3 (14.7) 89.6 (24.4)a 95.8 (25.5)a <0.001
Waist (cm) 84.8 (13.1) 101.3 (18.0)a 110.7 (18.8)a,b <0.001
BMI (kg/m2) 25.4 (4.9) 31.3 (8.2)a 35.2 (8.1)a,b <0.001
Current smokers (%) 7.8 (2.9;16.2) 6.3 (1.8;15.5) 11.8 (3.3;27.5) 0.660
Systolic blood pressure (mmHg) 118.7 (15.2) 128.8 (15.4)a 135.7 (13.8)a,b <0.001
Diastolic blood pressure (mm Hg) 74.2 (9.8) 77.5 (10.4)a 80.8 (6.8)a 0.003
Total cholesterol (mmol/L) 4.7 (0.9) 4.5 (1.0) 4.2 (1.0) 0.112
HDL cholesterol (mmol/L) 1.5 (0.6) 1.2 (0.4)a 1.1 (0.4)a <0.001
LDL cholesterol (mmol/L) 2.6 (0.9) 2.5 (1) 2.2 (0.8) 0.172
Triglycerides (mmol/L) 1.0 (0.7;1.6) 1.7 (1.1;2.7)a 1.7 (1.2;2.4)a <0.001
Antihypertensive treatment (%) 12.0 (5.6;21.6) 54.0 (40.9;66.6)a 52.9 (35.1;70.2)a <0.001
Lipid-lowering treatment (%) 4.0 (0.8;11.2) 52.4 (39.4;65.1)a 44.1 (27.2;62.1)a <0.001
HbA1c (%) 5.2 (0.3) 6.1 (0.6)
a 7.5 (1.2)a,b <0.001
HbA1c (mmol/mol) 33.3 (2.8) 43.4 (6.3)
a 58.1 (12.9)a,b <0.001
Preprandial glycemia
Pre-breakfast glucose (mmol/L) 5.8 (0.6) 7.2 (1.8)a 8.6 (2.8)a,b <0.001
Nocturnal glucose (mmol/L) 5.7 (0.9) 6.8 (1.2)a 8.1 (2.6)a,b <0.001
Postprandial glycemia
AUC glucose (h·mmol/L) 12.1 (1.6) 15.7 (3.3)a 20.0 (5.2)a,b <0.001
iAUC glucose (h·mmol/L) 0.5 (0.8) 1.9 (1.7)a 2.8 (2.5)a,b <0.001
iAUCbreakfast glucose (h·mmol/L) 0.6 (1.2) 2.5 (2.8)
a 4.0 (4.2)a,b <0.001
iAUClunch glucose (h·mmol/L) 0.7 (1.3) 1.7 (1.9)
a 2.5 (3.1)a <0.001
iAUCdinner glucose (h·mmol/L) 0.3 (1.2) 1.5 (2.5)
a 1.6 (2.5)a <0.001
Peak glucose (mmol/L) 8.9 (2.1) 12.0 (3.0)a 16.3 (3.8)a,b <0.001
Glycemic variability
MAGE (mmol/L) 1.5 (1.1;1.9) 2.8 (1.8;4.5)a 4.6 (3.2;6.4)a,b <0.001
SD (mmol/L) 0.8 (0.6;1.0) 1.5 (1.0;2.0)a 2.2 (1.6;2.6)a <0.001
CV (%) 13.6 (10.8;16.3) 19.8 (16.0;25.9)a 23.6 (18.4;30.4)a <0.001
Data are shown as means (SD), medians (interquartile range), or percentages (95% CI).
Pairwise differences are illustrated by letters: a P < 0.05 vs. no diabetes; b P < 0.05 vs. T2DHbA1c < 6.5%
Parameters with non-normally distributed values were log-transformed prior to the test.
AUC area under the curve for 2 h after meal intake, iAUC incremental area under the curve for 2 h after meal intake.
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Figures S2–S4. In all three groups, pre-breakfast glucose
was highly correlated with AUC glucose (P < 0.001), but
not with incremental AUC glucose (P ≥ 0.056).
Scatter plots of HbA1c measurements vs. measurements
of preprandial glucose (nocturnal and pre-breakfast glu-
cose), PPG (AUC glucose, incremental AUC glucose, and
peak glucose), and glycemic variability (MAGE, SD, and
CV) are shown in Fig. 1. All associations were statistically
signiﬁcant (P < 0.001), but with largest variation at higher
glycemic levels.
Unadjusted and adjusted associations of HbA1c with
glycemic markers by the three groups are shown in Fig. 2.
Total AUC glucose was more strongly associated with
HbA1c than the other glycemic markers in all three
groups, and this association was robust after adjustment
for confounders (Fig. 2) and for pre-breakfast glucose
concentrations (P ≤ 0.032 for all groups).
Among individuals without diabetes, pre-breakfast glu-
cose and AUC glucose were signiﬁcantly associated with
HbA1c before adjustment, but in the analyses adjusted for
age, sex, BMI, and ethnicity, only the association of AUC
glucose with HbA1c remained signiﬁcant (~2 mmol/mol
increase in HbA1c per SD increase in AUC glucose; Fig. 2).
In the T2DHbA1c < 6.5% group, all the glycemic variables
were signiﬁcantly associated with HbA1c and with largest
associations for nocturnal glucose and AUC glucose—also
after confounder adjustment except for CV (~3mmol/
mol increase in HbA1c per SD increase in the glycemic
variables; Fig. 2). For the T2DHbA1c ≥ 6.5% group, the
associations between glycemic variables and HbA1c were
overall stronger than in the other groups. For this group
both pre-breakfast glucose and nocturnal glucose as well
as AUC glucose, peak glucose, and SD of glucose were
signiﬁcantly associated with HbA1c both before and after
confounder adjustment and with a change in HbA1c of up
to 9mmol/mol per SD increase in glycemia (Fig. 2). The
incremental AUC was not associated with HbA1c in the
T2DHbA1c ≥ 6.5% group when considering all meals or when
studying breakfast, lunch, and dinner, separately (Sup-
plementary Figure S5).
Relative contributions of glycemic and non-glycemic
factors to variation in HbA1c
Figure 3 illustrates the proportion of variance in HbA1c
explained by preprandial glucose, PPG, glycemic varia-
bility, and non-glycemic factors in the three groups.
In the non-diabetic population, 35% of the variance in
HbA1c was explained by the included variables, and here
the included non-glycemic factors accounted for half of
the variance explained. Preprandial glucose explained 4%,
PPG 8%, and glycemic variability 7% of the variance in
HbA1c.
Among those with T2DHbA1c < 6.5%, 49% of the variance
in HbA1c was explained by the variables included in the
model. Here the contribution of non-glycemic factors was
small (5% of the variance explained), whereas preprandial
glucose, PPG, and glycemic variability explained 13, 17,
and 13%, respectively, of the variance in HbA1c.
For the T2DHbA1c≥6.5% group, 78% of the variance in
HbA1c could be explained by the non-glycemic and gly-
cemic factors included in the model. Preprandial and
postprandial glycemia explained similarly large propor-
tions (about 27% each) of the variance in HbA1c and
glycemic variability explained 20%. Again, non-glycemic
factors only explained 5% of the variance.
Inclusion of only pre-breakfast glucose, total AUC and
SD as measures of preprandial glycemic, postprandial
glycemia, and glycemic variability, respectively, reduced
the contributions from preprandial glucose and PPG to
HbA1c, especially in the T2DHbA1c < 6.5% group. The con-
tribution from glycemic variability was also reduced,
especially in the non-diabetic population and in the
T2DHbA1c ≥ 6.5% group (Supplementary Figure S6).
Discussion
In this analysis based on repeated CGM measurements
under free-living conditions, we found that PPG exposure
contributed more than preprandial glucose or glucose
variability exposure to variation in HbA1c in non-diabetic
individuals. In individuals with non-insulin-treated T2D,
preprandial glucose and PPG contributed equally and
slightly more than glycemic variability to variation in
HbA1c. We also showed that glycemic factors as well as
age, sex, BMI, and ethnicity accounted for only one-third
of the explained variance in HbA1c among individuals
without diabetes, whereas these same factors accounted
for nearly 80% of the explained variance in HbA1c among
non-insulin-treated T2D patients with HbA1c ≥ 6.5%.
Finally, we demonstrated that the contribution of non-
glycemic factors to the explained variance in HbA1c was
3–4 times higher in the non-diabetic population than in
those with T2D.
The frequent CGM measurement periods during free-
living conditions in combination with HbA1c measured by
high-quality techniques after 3 months of glucose expo-
sure made it possible to assess the contributions of real-
life glycemic exposures to the variation in HbA1c in a large
heterogeneous group of individuals with and without
T2D. HbA1c is a measure of the average blood glucose
concentration over the last 8–12 weeks and is determined
by glycemic as well as genetic, hematologic, and illness-
related factors1. Changes in the lifespan of the ery-
throcytes can therefore affect HbA1c concentrations, such
that a higher mean age of erythrocytes will lead to higher
HbA1c concentrations
1. The average survival of ery-
throcytes is slightly longer in men (117 days) than in
women (106 days), so also sex can confound HbA1c
concentrations in a given population. Accordingly, we
Færch et al. Nutrition and Diabetes  (2018) 8:38 Page 5 of 9
Nutrition and Diabetes
Fig. 1 Scatter plot of HbA1c measurements vs. measurements of pre-breakfast glucose (a), nocturnal glucose (b), AUC glucose (c), incremental AUC
glucose (d), peak glucose (e), MAGE (f), SD (g), and CV (h) obtained from continues glucose monitoring (P < 0.001 for all associations). Light blue: No
diabetes; blue: T2DHbA1c < 6.5%; dark blue: T2DHbA1c ≥ 6.5%
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adjusted for age and sex in our analyses. In the ADAG
study, individuals with anemia or with severe liver or renal
disease were excluded from participation in order to avoid
effects of iron deﬁciency anemia on HbA1c concentra-
tions. Factors, unrelated to age and sex, have been
examined in twin studies. In non-diabetic, healthy, female
twins with similar glucose tolerance, 62% of the between-
person variation in HbA1c was attributable to genetic
factors, with the remainder reﬂecting age and environ-
mental factors14. The relatively high contribution of non-
glycemic factors to HbA1c in non-diabetic individuals may
explain the relatively poor overlap among fasting glucose,
glucose tolerance, and HbA1c in this population
15, 16. This
also suggests that markers other than HbA1c might better
capture the relatively subtle differences in glycemia
among non-diabetic individuals17.
A number of observational studies have documented
associations of lower dietary glycemic index and glycemic
load with reduced risk of developing T2D and coronary
heart disease18, 19. Likewise, a large trial in individuals
with impaired glucose tolerance showed that adminis-
tration of acarbose (a PPG lowering drug) with meals
three times daily for 5 years reduced the incidence of
diabetes by 18% compared to placebo20. Together these
ﬁndings support the notion that modiﬁcation of PPG by
either diet or medication may have beneﬁcial con-
sequences for cardiometabolic health, including markers
of glycemic control and thus risk of diabetes. However,
the contributions to HbA1c of “usual,” real-time PPG
exposures has until now been unclear, because most
previous studies have assessed outcomes in relation to
either glycemic control in individuals or the glycemic
potential of foods. Former studies consider relationships
with individual variation in responses to standardized
meal tests, and not under free-living conditions8, 9. This is
Fig. 2 Mean (95% CI) difference in HbA1c by an SD difference in glycemia for participants without diabetes, T2DHbA1c < 6.5%: non-insulin-treated
diabetes and HbA1c < 6.5%/48mmol/mol or T2DHbA1c ≥ 6.5%: non-insulin-treated diabetes and HbA1c ≥ 6.5%/48mmol/mol. Estimated differences are
unadjusted (gray) or adjusted for age, sex, BMI, and ethnicity (black)
Fig. 3 Proportion of variance explained in HbA1c by non-glycemic
factors (age, sex, BMI, ethnicity), preprandial glucose (pre-breakfast and
nocturnal glucose), postprandial glucose (total and incremental area
under the curve as well as peak glucose), and glycemic variability
(MAGE, SD, and CV) by diabetes status and HbA1c levels.
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an important aspect because glucose concentrations after
a standard meal test mainly reﬂect the health status of an
individual (i.e., glucose tolerance, insulin resistance, and
β-cell capacity) but does not directly inform about the
actual, lifestyle-related glucose exposures in the previous
weeks to months. Alternatively, studies on the glycemic
potential of foods or diets (e.g., glycemic index or gly-
cemic load) consider relationships with foods or diets that
are known to differ in their relative glycemic impact (as
determined from standardized testing), but these also do
not quantify outcomes in relation to the actual levels and
variation in PPG over a sustained period of intervention
or observation.
Our ﬁnding that PPG, as estimated by the total AUC for
glucose following meals, seems to be the main contributor
to HbA1c in non-diabetic individuals provides a link
between PPG and HbA1c that supports the notion that
lower PPG is beneﬁcial in terms of preventing future
diabetes and reducing risk for cardiovascular disease4, 18, 19.
However, in our study population each SD higher AUC
was associated with a 0.2%-point (2 mmol/mol) higher
HbA1c, indicating that the magnitude of the association
was rather modest.
Another aspect of PPG is glycemic variability, which was
associated with HbA1c in individuals with non-insulin-
treated T2D, but not in individuals without diabetes. In the
non-diabetic population mean MAGE was 1.5, which is 2–3
times lower than in the diabetes population. Other studies
have estimated MAGE to be between 1.6 and 1.8 in non-
diabetic individuals21–23, underscoring that the non-diabetic
individuals included in the ADAG study are healthier than
the general non-diabetic population.
Overall, we found that preprandial and PPG explained
an equal amount of variance in HbA1c in individuals with
T2D. Furthermore, glycemic features explained a much
larger proportion of the variation in those with T2D than
in the non-diabetic population. Other studies using CGM
for assessment of glycemia under free-living conditions
have also found equal contributions of fasting and post-
prandial hyperglycemia to HbA1c in patients with T2D,
but with a tendency of a greater contribution of PPG at
lower HbA1c concentrations and higher contribution of
fasting hyperglycemia at higher HbA1c concentrations
24–26.
The latter result is in accordance with the ﬁndings by
Monnier et al.9 who suggested that the relative con-
tribution of PPG decreased, whereas the relative con-
tribution of fasting glucose increased, from the lowest to
the highest HbA1c quintile among non-insulin-treated
T2D patients with HbA1c ranging from ~6 to 12%
(42–108mmol/mol). The use of CGM to measure real-life
exposures in the entire study population and the exclu-
sion of individuals treated with insulin in our study are
likely to explain the differences between our results and
the results by Monnier et al9.
A limitation of our study was the observational design,
which limited the possibility to study whether differences
in PPG exposures were caused by lifestyle behaviors or
use of oral glucose-lowering medications (in T2D only)
during the measurement periods or whether they were
due to pre-existing glucose intolerance/insulin resistance.
We used “pre-breakfast” glucose concentrations as base-
line in the calculation of the incremental AUC, which
appeared higher than the fasting glucose concentrations
measured during screening. Accordingly, the true PPG
exposures may have been underestimated and the pre-
breakfast exposures overestimated in our study. Another
limitation was that information on physical activity and
dietary intake was not collected concomitant with the
CGM periods. Such information would be relevant to
collect in future studies, particularly in individuals with-
out diabetes, in order to understand how different foods,
eating patterns, or exercise bouts as well as timing of
eating affect daily blood glucose concentrations, peak
glucose, and overall glycemia.
In conclusion, we found that PPG exposure contributed
more than preprandial glucose or glucose variability to
variation in HbA1c in non-diabetic individuals, whereas
preprandial glycemia and postprandial glycemia con-
tributed equally to the variation in HbA1c in individuals
with T2D. We could only explain one-third of the var-
iance in HbA1c by glycemic factors, age, sex, BMI, and
ethnicity among individuals without diabetes, whereas
these factors explained nearly 80% of the variance in
HbA1c among non-insulin-treated T2D patients with
HbA1c concentrations ≥6.5%. Knowledge from this study
can be useful to predict clinically meaningful effects on
HbA1c of dietary interventions targeting PPG in non-
diabetic and non-insulin-treated individuals with T2D
with a wide range of glycemic control.
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